|
Genomic characterization of the GATA3 mutational landscape in breast cancer. |
|
|
Honoraria - BostonGene; Cardinal Health; GE Healthcare; Napo Pharmaceuticals |
Speakers' Bureau - BostonGene |
|
|
Employment - MD Anderson Cancer Center |
Consulting or Advisory Role - Abbvie; Apeiron Biologics; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Lengo Therapeutics; Loxo; Menarini Group; OnCusp Therapeutics; PACT Pharmaceuticals; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Theratechnologies; Tyra Biosciences; Xencor; Zentalis; Zymeworks |
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - ESMO; European Organisation for Research and Treatment of Cancer (EORTC) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - BostonGene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Personalis; Pfizer; Sermonix Pharmaceuticals |
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Novartis |
|
|
Consulting or Advisory Role - Taiho Oncology |
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Guardant Health (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst) |